Uso de rituximab (anticuerpo monoclonal anti-CD20) en lupus eritematoso sistémico refractario a tratamiento: Caso clínico
| Author | dc.contributor.author | Sabugo Siraqyan, María Francisca | |
| Author | dc.contributor.author | Llanos M., Carolina | es_CL |
| Author | dc.contributor.author | Soto Sáez, Lilian | es_CL |
| Author | dc.contributor.author | Gutiérrez, Jorge | es_CL |
| Author | dc.contributor.author | Cuchacovich Turteltaub, Miguel | es_CL |
| Admission date | dc.date.accessioned | 2014-08-29T16:34:50Z | |
| Available date | dc.date.available | 2014-08-29T16:34:50Z | |
| Publication date | dc.date.issued | 2005 | |
| Cita de ítem | dc.identifier.citation | Rev Méd Chile 2005; 133: 681-684 | en_US |
| Identifier | dc.identifier.issn | 0034-9887 | |
| Identifier | dc.identifier.uri | https://repositorio.uchile.cl/handle/2250/129321 | |
| General note | dc.description | Artículo de publicación SciELO | en_US |
| Abstract | dc.description.abstract | New therapeutic approaches that include depletion of B cells using rituximab, a chimeric monoclonal antibody directed against the B cell specific antigen CD-20 have been developed for the treatment of systemic lupus erythematosus (SLE). We report the case of a 18 years old girl with SLE that did not respond and experienced adverse effects with the use of hydroxycloroquine, methotrexate, mycophenolate mofetil, azathioprine and high-dose steroids. Rituximab was given weekly at 375 mg/m2 for four doses. The drug was well tolerated and the patient had no adverse reactions. She remains asymptomatic three months later | en_US |
| Lenguage | dc.language.iso | es | en_US |
| Publisher | dc.publisher | Sociedad Médica de Santiago | en_US |
| Type of license | dc.rights | Attribution-NonCommercial-NoDerivs 3.0 Chile | * |
| Link to License | dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/cl/ | * |
| Keywords | dc.subject | Lupus erythematosus, systemic | en_US |
| Título | dc.title | Uso de rituximab (anticuerpo monoclonal anti-CD20) en lupus eritematoso sistémico refractario a tratamiento: Caso clínico | en_US |
| Title in another language | dc.title.alternative | Rituximab (anti-CD20 monoclonal antibody) for refractory systemic lupus erythematosus. Report of one case | en_US |
| Document type | dc.type | Artículo de revista |
Files in this item
This item appears in the following Collection(s)
-
Artículos de revistas
Artículos de revistas
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Chile